Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1
1(33.3%)
Phase 1
1(33.3%)
Phase 2
1(33.3%)
3Total
Early Phase 1(1)
Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05056194Phase 2Withdrawn

Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease Study

Role: lead

NCT04966832Phase 1Completed

Safety, Tolerability and Pharmacokinetics of XW10508 Immediate and Modified Release Formulations in Healthy Adults

Role: lead

NCT04688580Early Phase 1Completed

Pharmacokinetics, Safety, and Tolerability of Various XW10172 Oral Formulations in Healthy Adult Volunteers

Role: lead

All 3 trials loaded